Login / Signup

The crosstalk between ubiquitination and endocrine therapy.

Yidong GeZiqing ZhanMeng YeXiaofeng Jin
Published in: Journal of molecular medicine (Berlin, Germany) (2023)
Endocrine therapy (ET), also known as hormone therapy, refers to the treatment of tumors by regulating and changing the endocrine environment and hormone levels. Its related mechanism is mainly through reducing hormone levels and blocking the binding of hormones to corresponding receptors, thus blocking the signal transduction pathway to stimulate tumor growth. However, with the application of ET, some patients show resistance to ET, which is attributed to abnormal accumulation of hormone receptors (HRs) and the production of multiple mutants of HRs. The targeted degradation of abnormal accumulation protein mediated by ubiquitination is an important approach that regulates the protein level and function of intracellular proteins in eukaryotes. Here, we provide a brief description of the traditional and novel drugs available for ET in this review. Then, we introduce the link between ubiquitination and ET. In the end, we elaborate the clinical application of ET combined with ubiquitination-related molecules. KEY MESSAGES: • A brief description of the traditional and novel drugs available for endocrine therapy (ET). • The link between ubiquitination and ET. • The clinical application of ET combined with ubiquitination-related molecules.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • binding protein
  • mesenchymal stem cells
  • protein protein
  • peritoneal dialysis
  • amino acid
  • cancer therapy
  • drug delivery
  • dna binding
  • patient reported